| 1 |
33634586 |
10.1002/cyto.b.21995 |
2022 |
Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. |
MYD88 |
| 2 |
33682304 |
10.1002/cyto.b.22000 |
2022 |
VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. |
MYD88 |
| 3 |
34325497 |
10.4143/crt.2021.752 |
2022 |
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. |
MYD88 |
| 4 |
34411492 |
10.1139/cjpp-2021-0007 |
2022 |
Colchicine attenuates renal ischemia-reperfusion-induced liver damage: implication of TLR4/NF-κB, TGF-β, and <i>BAX</i> and <i>Bcl-2</i> gene expression. |
MYD88 |
| 5 |
34448823 |
10.1182/bloodadvances.2021004212 |
2022 |
The molecular hallmarks of primary and secondary vitreoretinal lymphoma. |
MYD88 |
| 6 |
34638136 |
10.1182/bloodadvances.2020003698 |
2022 |
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. |
MYD88 |
| 7 |
34654055 |
10.1182/bloodadvances.2021006034 |
2022 |
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. |
MYD88 |
| 8 |
34674984 |
10.1016/j.clml.2021.09.014 |
2022 |
Bing-Neel Syndrome: Update on the Diagnosis and Treatment. |
MYD88 |
| 9 |
34793256 |
10.1200/JCO.21.01194 |
2022 |
Venetoclax in Previously Treated Waldenström Macroglobulinemia. |
MYD88 |
| 10 |
34802044 |
10.1038/s41379-021-00954-z |
2022 |
A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. |
MYD88 |
| 11 |
34895930 |
10.1016/j.pathol.2021.09.018 |
2022 |
Cutaneous lymphoplasmacytic lymphoma with MYD88 L265P mutation, bone marrow involvement, and paraproteinaemia. |
MYD88 |
| 12 |
34961399 |
10.1080/10428194.2021.2018584 |
2022 |
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. |
MYD88 |
| 13 |
34980578 |
10.1016/j.clml.2021.11.014 |
2022 |
SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions. |
MYD88 |
| 14 |
34997652 |
10.1111/ejh.13736 |
2022 |
Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma. |
MYD88 |
| 15 |
35020191 |
10.1111/bjh.18036 |
2022 |
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. |
MYD88 |
| 16 |
35028710 |
10.1007/s00428-021-03265-5 |
2022 |
Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. |
MYD88 |
| 17 |
35030632 |
10.1182/bloodadvances.2021006410 |
2022 |
Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. |
MYD88 |
| 18 |
35044826 |
10.1126/sciadv.abl4644 |
2022 |
Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma. |
MYD88 |
| 19 |
35073397 |
10.1039/d1lc01055g |
2022 |
Direct MYD88<sup>L265P</sup> gene detection for diffuse large B-cell lymphoma (DLBCL) <i>via</i> a miniaturised CRISPR/dCas9-based sensing chip. |
MYD88 |
| 20 |
35096069 |
10.1155/2022/1182384 |
2022 |
Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia). |
MYD88 |
| 21 |
35106936 |
10.1002/cam4.4550 |
2022 |
SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. |
MYD88 |
| 22 |
35126963 |
10.1177/20406207211072839 |
2022 |
MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. |
MYD88 |
| 23 |
35142151 |
10.3324/haematol.2021.279908 |
2022 |
A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas. |
MYD88 |
| 24 |
35149375 |
10.1016/j.ctarc.2022.100527 |
2022 |
Current approach to Waldenström Macroglobulinemia. |
MYD88 |
| 25 |
35154721 |
10.1002/ccr3.5372 |
2022 |
Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma. |
MYD88 |
| 26 |
35156897 |
10.1080/21655979.2022.2032939 |
2022 |
MicroRNA-885-3p alleviates bronchial epithelial cell injury induced by lipopolysaccharide via toll-like receptor 4. |
MYD88 |
| 27 |
35158867 |
10.3390/cancers14030598 |
2022 |
Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools. |
MYD88 |
| 28 |
35169086 |
10.11477/mf.1436204531 |
2022 |
[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. |
MYD88 |
| 29 |
35200564 |
10.3390/curroncol29020065 |
2022 |
Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology. |
MYD88 |
| 30 |
35210172 |
10.1016/j.preteyeres.2022.101053 |
2022 |
Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches. |
MYD88 |
| 31 |
35223507 |
10.3389/fonc.2022.824632 |
2022 |
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. |
MYD88 |
| 32 |
35236331 |
10.1186/s12885-022-09237-5 |
2022 |
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. |
MYD88 |
| 33 |
35255429 |
10.1016/j.anndiagpath.2021.151886 |
2022 |
De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. |
MYD88 |
| 34 |
35255496 |
10.1182/bloodadvances.2021006147 |
2022 |
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. |
MYD88 |
| 35 |
35265542 |
10.12890/2022_003106 |
2022 |
Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression. |
MYD88 |
| 36 |
35267569 |
10.3390/cancers14051264 |
2022 |
The Biology of Ocular Adnexal Marginal Zone Lymphomas. |
MYD88 |
| 37 |
35281910 |
10.3389/fphar.2022.857869 |
2022 |
Engineered Bacteria EcN-MT Alleviate Liver Injury in Cadmium-Exposed Mice <i>via</i> its Probiotics Characteristics and Expressing of Metallothionein. |
MYD88 |
| 38 |
35300216 |
10.2147/JIR.S341355 |
2022 |
The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 39 |
35339405 |
10.1016/j.clml.2022.02.005 |
2022 |
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. |
MYD88 |
| 40 |
35339566 |
10.1016/j.humpath.2022.03.008 |
2022 |
Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. |
MYD88 |
| 41 |
35340094 |
10.1111/vco.12816 |
2022 |
Anticancer activity of IRAK-4 inhibitors against canine lymphoid malignancies. |
MYD88 |
| 42 |
35358350 |
10.1002/ajh.26552 |
2022 |
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. |
MYD88 |
| 43 |
35359040 |
10.3760/cma.j.cn112151-20211220-00915 |
2022 |
[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma]. |
MYD88 |
| 44 |
35370644 |
10.3389/fphar.2022.842723 |
2022 |
Baicalein Ameliorates Myocardial Ischemia Through Reduction of Oxidative Stress, Inflammation and Apoptosis via TLR4/MyD88/MAPK<sub>S</sub>/NF-κB Pathway and Regulation of Ca<sup>2+</sup> Homeostasis by L-type Ca<sup>2+</sup> Channels. |
MYD88 |
| 45 |
35401516 |
10.3389/fimmu.2022.842439 |
2022 |
Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. |
MYD88 |
| 46 |
35454017 |
10.3390/diagnostics12040969 |
2022 |
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. |
MYD88 |
| 47 |
35506035 |
10.5114/wo.2022.115675 |
2022 |
Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients - an immunohistochemical study. |
MYD88 |
| 48 |
35510210 |
10.1177/20406207221093962 |
2022 |
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. |
MYD88 |
| 49 |
35514998 |
10.3389/fimmu.2022.894464 |
2022 |
Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome. |
MYD88 |
| 50 |
35537114 |
10.1182/bloodadvances.2022007279 |
2022 |
Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM. |
MYD88 |
| 51 |
35538064 |
10.1038/s41467-022-30050-y |
2022 |
The genomic and transcriptional landscape of primary central nervous system lymphoma. |
MYD88 |
| 52 |
35554927 |
10.1002/eji.202149746 |
2022 |
Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas. |
MYD88 |
| 53 |
35628381 |
10.3390/ijms23105570 |
2022 |
<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. |
MYD88 |
| 54 |
35646048 |
10.3389/fgene.2022.878618 |
2022 |
Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. |
MYD88 |
| 55 |
35680596 |
10.3760/cma.j.issn.0253-2727.2022.05.007 |
2022 |
[Exploring the detection of MYD88 mutation in patients with Waldenström macroglobulinemia by different methods and specimens]. |
MYD88 |
| 56 |
35759728 |
10.1182/blood.2022015926 |
2022 |
Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. |
MYD88 |
| 57 |
35761836 |
10.1155/2022/3864863 |
2022 |
Mesenchymal Stem Cell Exosomal miR-146a Mediates the Regulation of the TLR4/MyD88/NF-<i>κ</i>B Signaling Pathway in Inflammation due to Diabetic Retinopathy. |
MYD88 |
| 58 |
35794278 |
10.1007/s00277-022-04910-y |
2022 |
First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia. |
MYD88 |
| 59 |
35813102 |
10.1097/HS9.0000000000000746 |
2022 |
Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline. |
MYD88 |
| 60 |
35877223 |
10.3390/curroncol29070363 |
2022 |
Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. |
MYD88 |
| 61 |
35879731 |
10.1186/s40364-022-00401-4 |
2022 |
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. |
MYD88 |
| 62 |
35903524 |
10.1016/j.jsps.2022.05.009 |
2022 |
Genistein promotes M1 macrophage apoptosis and reduces inflammatory response by disrupting miR-21/TIPE2 pathway. |
MYD88 |
| 63 |
35911113 |
10.3389/fnut.2022.907386 |
2022 |
Selenium Nanoparticles Improved Intestinal Health Through Modulation of the NLRP3 Signaling Pathway. |
MYD88 |
| 64 |
35928872 |
10.3389/fonc.2022.932674 |
2022 |
Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma. |
MYD88 |
| 65 |
35932039 |
10.1186/s13000-022-01244-1 |
2022 |
Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma. |
MYD88 |
| 66 |
35937947 |
10.1155/2022/6441139 |
2022 |
Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis. |
MYD88 |
| 67 |
35939775 |
10.1200/GO.21.00380 |
2022 |
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. |
MYD88 |
| 68 |
35949601 |
10.3892/ol.2022.13418 |
2022 |
Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report. |
MYD88 |
| 69 |
35952646 |
10.1016/j.chom.2022.07.003 |
2022 |
Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis. |
MYD88 |
| 70 |
35952929 |
10.1016/j.oret.2022.08.005 |
2022 |
Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A potential less-invasive method for diagnosis and treatment response assessment. |
MYD88 |
| 71 |
35968590 |
10.3760/cma.j.issn.0253-2727.2022.06.006 |
2022 |
[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]. |
MYD88 |
| 72 |
35973369 |
10.1016/j.intimp.2022.109138 |
2022 |
Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization. |
MYD88 |
| 73 |
36003901 |
10.2147/BLCTT.S259860 |
2022 |
Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice. |
MYD88 |
| 74 |
36006771 |
10.1097/PAS.0000000000001957 |
2022 |
Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study. |
MYD88 |
| 75 |
36051079 |
10.1002/jha2.428 |
2022 |
Targetable alterations in primary extranodal diffuse large B-cell lymphoma. |
MYD88 |
| 76 |
36053490 |
10.1002/hon.3073 |
2022 |
Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma. |
MYD88 |
| 77 |
36055572 |
10.1016/j.clim.2022.109105 |
2022 |
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. |
MYD88 |
| 78 |
36059608 |
10.3389/fonc.2022.955080 |
2022 |
Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis. |
MYD88 |
| 79 |
36081566 |
10.3389/fonc.2022.941347 |
2022 |
Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. |
MYD88 |
| 80 |
31418635 |
10.1080/09273948.2019.1636093 |
2021 |
PreservCyt Is an Optimal Fixative that Permits Cytologic and Molecular Analyses of Vitreoretinal Lymphoma Biopsies. |
MYD88 |
| 81 |
31603365 |
10.1080/09273948.2019.1657903 |
2021 |
Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction. |
MYD88 |
| 82 |
32139889 |
10.1038/s41375-020-0766-4 |
2021 |
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. |
MYD88 |
| 83 |
32447345 |
10.1038/s41375-020-0874-1 |
2021 |
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response. |
MYD88 |
| 84 |
32583848 |
10.1093/neuonc/noaa145 |
2021 |
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. |
MYD88 |
| 85 |
32591642 |
10.1038/s41375-020-0934-6 |
2021 |
Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. |
MYD88 |
| 86 |
32810857 |
10.1159/000509286 |
2021 |
Current and Emerging Treatments for Waldenström Macroglobulinemia. |
MYD88 |
| 87 |
32845738 |
10.1080/09273948.2020.1787460 |
2021 |
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center. |
MYD88 |
| 88 |
32965155 |
10.1080/09273948.2020.1802488 |
2021 |
Serial Detection of <i>MYD88</i> L265P Mutation in the Aqueous Humor of a Patient with Vitreoretinal Lymphoma for Disease Monitoring. |
MYD88 |
| 89 |
32970964 |
10.1165/rcmb.2020-0083OC |
2021 |
<i>Aspergillus</i> <i>fumigatus</i> Recognition by Dendritic Cells Negatively Regulates Allergic Lung Inflammation through a TLR2/MyD88 Pathway. |
MYD88 |
| 90 |
32973328 |
10.1038/s41379-020-00685-7 |
2021 |
The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. |
MYD88 |
| 91 |
33025009 |
10.1182/blood.2020004918 |
2021 |
MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis. |
MYD88 |
| 92 |
33079297 |
10.1007/s10014-020-00386-8 |
2021 |
Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas. |
MYD88 |
| 93 |
33202420 |
10.1182/blood.2020008520 |
2021 |
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. |
MYD88 |
| 94 |
33217360 |
10.1016/j.hemonc.2020.10.003 |
2021 |
Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. |
MYD88 |
| 95 |
33221324 |
10.1016/j.ophtha.2020.11.018 |
2021 |
Single B-Cell Genomic Analyses Differentiate Vitreoretinal Lymphoma from Chronic Inflammation. |
MYD88 |
| 96 |
33222046 |
10.1007/s12185-020-03038-x |
2021 |
Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome. |
MYD88 |
| 97 |
33232972 |
10.1182/blood.2020005244 |
2021 |
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. |
MYD88 |
| 98 |
33263441 |
10.1080/17474086.2021.1856652 |
2021 |
Development of molecular intervention strategies for B-cell lymphoma. |
MYD88 |
| 99 |
33311649 |
10.1038/s41379-020-00720-7 |
2021 |
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. |
MYD88 |
| 100 |
33368476 |
10.1002/ajh.26082 |
2021 |
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. |
MYD88 |
Datasets
Models
